A recent article published in The Review of Myopia Management by Thomas Naduvilath, Msc Biostatistics, PhD, the Head of Biostatistics at BHVI, looked at the question: Are Axial Length & Percentile Curves the New Standard?
It concluded that:
“It has been recommended that axial length be considered the primary outcome for determining progression and that practitioners adopt axial length measurements in managing myopia.”
However, it also stated that:
“Despite technological advancements in the measurement of axial length, using an optical biometer as a gold standard remains a challenge, particularly with the high-cost differential between instruments.”
The Occuity AX1 will not only be non-contact, handheld and portable and therefore easier to use with children, it will also be very cost-effective. With myopia a global challenge and the growth of myopia management treatments increasing, at Occuity we believe the AX1 will revolutionise the way in which Axial length is measured.
Synopsis:
The increasing use of axial length measurements is challenging traditional refractive error measurements for monitoring myopia progression. Axial length measurements offer significant advantages over refractive error measurements, especially in assessing young children and situations where cycloplegic assessment is not feasible. Axial length is recommended as the primary outcome measure for determining myopia progression and evaluating the effectiveness of myopia control treatments. Population-specific percentile charts based on axial length provide valuable tools for monitoring myopia risk and progression. Despite challenges like the high cost of optical biometers and the lack of agreed-upon classification thresholds, axial length measurements are gaining prominence in myopia research. By embracing axial length measurements, clinicians can make more informed decisions and work towards reducing the long-term impact of myopia-related eye diseases.